echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dr. Zhang Lianshan of Hengrui Pharmaceuticals on "The Pain points and hopes of Chinese Pharmaceutical Innovation"

    Dr. Zhang Lianshan of Hengrui Pharmaceuticals on "The Pain points and hopes of Chinese Pharmaceutical Innovation"

    • Last Update: 2020-08-20
    • Source: Internet
    • Author: User
    Tags

    ich

    drugs

    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In 2019, 60 new drugs were approved in China for the first time, including more than 10 domestic new drugs, accounting for more than 20%, a new record.
    innovative drugs have become an important growth engine for pharmaceutical companies and The Chinese pharmaceutical market, and local innovative enterprises are becoming a new force in the biopharmaceutical sector in China.
    , however, even if this era has given the soil of pharmaceutical innovation, China's innovative pharmaceutical industry is still facing difficulties and challenges. Dr. Zhang Lianshan, Deputy General Manager of Hengrui Pharmaceuticals,
    , graduated from Nanjing Pharmaceutical College (now China University of Pharmacy) and ph.D. in Chemistry at Tubingen University in Germany.
    has been engaged in postdoctoral research at Tubingen University and Vanderbilt University Medical Center in the United States.
    was hired by Lilly to develop new drugs for diabetes and obesity and was the inventor of Lilly's GLP-1 agonists and long-acting insulin.
    later joined Marcadia Biopharmaceuticals as Senior Chemical Director, successfully developing five clinical compounds.
    is currently a director, deputy general manager and president of global research and development of Jiangsu Hengrui Pharmaceuticals.
    is also an industry professor at China Pharmaceutical University and an expert in the review of the overall group of major new drug creations in China.
    at present, Dr. Zhang Lianshan is committed to combining foreign experience in the development of new drug products and management concepts with HengRui's existing systems to strengthen the research and development of new drugs for oncology, diabetes and cardiovascular disease, and to expand the field of protein and antibody biologic drugs.
    is definitely a strong player with academic, research and development experience and industry experience. Dr. Zhang Lianshan,
    , first gave a comprehensive explanation of the development process of global innovative drugs (five stages): Dr. Zhang Lianshan then deeply analyzed the driving factors of research and development of innovative drugs, the current situation of the development of innovative drugs, the development trend of innovative drugs in China, and how innovative pharmaceutical enterprises determine the direction of research and development on the basis of balancing market principles and scientific efficiency. The driving factors of
    innovative drug research and development mainly include the change of disease spectrum, the development of basic research/biotechnology and the high concentration of pharmaceutical industry clusters.
    the disease spectrum of our country from the initial 60's and 70's anti-infective drugs, to the cardiovascular drugs in the 90's, to the anti-tumor target drugs after 2000.
    during this period, the continuous progress of life sciences, such as DNA recombination technology, monoclonal antibody technology, targeted therapy, tumor immunotherapy, etc., have effectively promoted and accelerated the development of innovative drugs.
    on the current situation of the development of innovative drugs, Dr. Zhang Lianshan said that policy, capital and internationalization have created a new environment for the development of China's innovative drugs: from the national policy level, state agencies have issued continuous texts (such as the State Council issued No. 44, the new Drug Administration Law, the 2019 edition of the health insurance catalog adjustment so as to lay a policy foundation for the development of innovative pharmaceutical industry, from the capital market, the successive opening of Hong Kong stocks and science and technology boards has brought more sources of funding for domestic innovative pharmaceutical enterprises, and from the international integration, China's accession to ICH directly brings China's innovative pharmaceutical industry to the international series, bringing domestic innovative drugs to a larger stage.
    but homogenization research and development phenomenon is serious and generic drug production is also the current dilemma of China's innovative drug market.
    but very pleased that the current state through a series of policies to strongly support and encourage innovative drugs, China's innovative drugs are bound to show a good trend of development.
    according to the construction of "Healthy China", the total size of China's health services industry will reach 16 trillion yuan by 2030;
    as the supply of belt continues to deepen, in addition to the price of many drugs water is squeezed out, the process of industry reshuffle also began to accelerate.
    and focusoning on monitoring the release of the drug catalog requires pharmaceutical companies to re-adjust their strategic layout, optimize their product lines and reform their marketing models.
    more and more Chinese pharmaceutical sinopers have been recognized by the international market, more Chinese pharmaceutical companies and overseas capital, enterprises, research institutions, platform cooperation, accelerate the pace of international integration.
    this set of policy factors will also promote the prosperity of the innovative drug market.
    finally Dr. Zhang Lianshan answered how innovative pharmaceutical companies determine the direction of research and development.
    he suggested that the research and development cycle of new drugs is very long, the biggest principle is patient-centered, followed by the combination of the enterprise's own research and development field and market demand.
    Hengrui Pharmaceuticals has many years of layout practice in the field of oncology, but to select a good target challenge is still very big, with domestic and foreign top research institutions to avoid a lot of detours.
    , the development of the biopharmaceutical industry is closely related to the development of life science research.
    at the same time, Dr. Zhang Lianshan suggested that the state set up a similar NIH institutions to increase scientific research investment in the field of health, because the investment in research and the training of talent is always the most important in the industry. In the end
    , Professor Xue Yu thanked Dr. Zhang Lianshan for his sharing and analysis, thanked Hengrui Pharmaceuticals for making good explorations in the field of research and development of innovative drugs, and hoped that more local enterprises could move towards the path of innovation and promote the development of national health and medicine.
    pharmaceutical innovation is of great practical significance and strategic significance to the development of Chinese medicine.
    hopes that in the near future, China will be able to establish a global research and development platform in line with the world.
    hope that we will work together to promote the development of China's national health and medicine industry, which also requires Chinese pharmaceutical people to pay double efforts, to maintain patience, to maintain perseverance, pay sincerity.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.